Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly in Semi-Immune Adults: A Phase 1, Double-Blinded Placebo Controlled Dosage Escalation Study
The erythrocyte binding antigen region II (EBA-175 RII) is a Plasmodium falciparum ligand that mediates erythrocyte invasion and is considered an important malaria vaccine candidate. A phase Ia trial in malaria naïve adults living in the United States found the recombinant non-glycosylated vaccine a...
Saved in:
| Published in | PloS one Vol. 11; no. 9; p. e0163066 |
|---|---|
| Main Authors | , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Public Library of Science
19.09.2016
Public Library of Science (PLoS) |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1932-6203 1932-6203 |
| DOI | 10.1371/journal.pone.0163066 |
Cover
| Abstract | The erythrocyte binding antigen region II (EBA-175 RII) is a Plasmodium falciparum ligand that mediates erythrocyte invasion and is considered an important malaria vaccine candidate. A phase Ia trial in malaria naïve adults living in the United States found the recombinant non-glycosylated vaccine antigen, EBA-175 RII-NG adjuvanted with aluminium phosphate to be safe, immunogenic and capable of inducing biologically active antibodies that can inhibit parasite growth in vitro. The aim of the current study was to assess the safety and immunogenicity of this vaccine in malaria exposed semi-immune healthy adults living in a malaria endemic country, Ghana. In this double-blinded, placebo controlled, dose escalation phase I trial, eighteen subjects per group received ascending dose concentrations (5 μg, 20 μg or 80 μg) of the vaccine intramuscularly at 0, 1 and 6 months, while 6 subjects received placebo (normal saline). The primary end point was the number of subjects experiencing Grade 3 systemic or local adverse events within 14 days post-vaccination. Serious adverse events were assessed throughout the study period. Blood samples for immunological analyses were collected at days 0, 14, 28, 42, 180 and 194. A total of 52 subjects received three doses of the vaccine in the respective groups. No serious adverse events were reported. The majority of all adverse events reported were mild to moderate in severity, with local pain and tenderness being the most common. All adverse events, irrespective of severity, resolved without any sequelae. Subjects who received any of the EBA-175 RII-NG doses had high immunoglobulin G levels which moderately inhibited P. falciparum growth in vitro, compared to those in the placebo group. In conclusion, the EBA-175 RII-NG vaccine was safe, well tolerated and immunogenic in malaria semi-immune Ghanaian adults. Its further development is recommended.
ClinicalTrials.gov. Identifier: NCT01026246. |
|---|---|
| AbstractList | The erythrocyte binding antigen region II (EBA-175 RII) is a Plasmodium falciparum ligand that mediates erythrocyte invasion and is considered an important malaria vaccine candidate. A phase Ia trial in malaria naïve adults living in the United States found the recombinant non-glycosylated vaccine antigen, EBA-175 RII-NG adjuvanted with aluminium phosphate to be safe, immunogenic and capable of inducing biologically active antibodies that can inhibit parasite growth in vitro. The aim of the current study was to assess the safety and immunogenicity of this vaccine in malaria exposed semi-immune healthy adults living in a malaria endemic country, Ghana. In this double-blinded, placebo controlled, dose escalation phase I trial, eighteen subjects per group received ascending dose concentrations (5 μg, 20 μg or 80 μg) of the vaccine intramuscularly at 0, 1 and 6 months, while 6 subjects received placebo (normal saline). The primary end point was the number of subjects experiencing Grade 3 systemic or local adverse events within 14 days post-vaccination. Serious adverse events were assessed throughout the study period. Blood samples for immunological analyses were collected at days 0, 14, 28, 42, 180 and 194. A total of 52 subjects received three doses of the vaccine in the respective groups. No serious adverse events were reported. The majority of all adverse events reported were mild to moderate in severity, with local pain and tenderness being the most common. All adverse events, irrespective of severity, resolved without any sequelae. Subjects who received any of the EBA-175 RII-NG doses had high immunoglobulin G levels which moderately inhibited P. falciparum growth in vitro, compared to those in the placebo group. In conclusion, the EBA-175 RII-NG vaccine was safe, well tolerated and immunogenic in malaria semi-immune Ghanaian adults. Its further development is recommended.The erythrocyte binding antigen region II (EBA-175 RII) is a Plasmodium falciparum ligand that mediates erythrocyte invasion and is considered an important malaria vaccine candidate. A phase Ia trial in malaria naïve adults living in the United States found the recombinant non-glycosylated vaccine antigen, EBA-175 RII-NG adjuvanted with aluminium phosphate to be safe, immunogenic and capable of inducing biologically active antibodies that can inhibit parasite growth in vitro. The aim of the current study was to assess the safety and immunogenicity of this vaccine in malaria exposed semi-immune healthy adults living in a malaria endemic country, Ghana. In this double-blinded, placebo controlled, dose escalation phase I trial, eighteen subjects per group received ascending dose concentrations (5 μg, 20 μg or 80 μg) of the vaccine intramuscularly at 0, 1 and 6 months, while 6 subjects received placebo (normal saline). The primary end point was the number of subjects experiencing Grade 3 systemic or local adverse events within 14 days post-vaccination. Serious adverse events were assessed throughout the study period. Blood samples for immunological analyses were collected at days 0, 14, 28, 42, 180 and 194. A total of 52 subjects received three doses of the vaccine in the respective groups. No serious adverse events were reported. The majority of all adverse events reported were mild to moderate in severity, with local pain and tenderness being the most common. All adverse events, irrespective of severity, resolved without any sequelae. Subjects who received any of the EBA-175 RII-NG doses had high immunoglobulin G levels which moderately inhibited P. falciparum growth in vitro, compared to those in the placebo group. In conclusion, the EBA-175 RII-NG vaccine was safe, well tolerated and immunogenic in malaria semi-immune Ghanaian adults. Its further development is recommended.ClinicalTrials.gov. Identifier: NCT01026246.TRIAL REGISTRATIONClinicalTrials.gov. Identifier: NCT01026246. The erythrocyte binding antigen region II (EBA-175 RII) is a Plasmodium falciparum ligand that mediates erythrocyte invasion and is considered an important malaria vaccine candidate. A phase Ia trial in malaria naïve adults living in the United States found the recombinant non-glycosylated vaccine antigen, EBA-175 RII-NG adjuvanted with aluminium phosphate to be safe, immunogenic and capable of inducing biologically active antibodies that can inhibit parasite growth in vitro . The aim of the current study was to assess the safety and immunogenicity of this vaccine in malaria exposed semi-immune healthy adults living in a malaria endemic country, Ghana. In this double-blinded, placebo controlled, dose escalation phase I trial, eighteen subjects per group received ascending dose concentrations (5 μg, 20 μg or 80 μg) of the vaccine intramuscularly at 0, 1 and 6 months, while 6 subjects received placebo (normal saline). The primary end point was the number of subjects experiencing Grade 3 systemic or local adverse events within 14 days post-vaccination. Serious adverse events were assessed throughout the study period. Blood samples for immunological analyses were collected at days 0, 14, 28, 42, 180 and 194. A total of 52 subjects received three doses of the vaccine in the respective groups. No serious adverse events were reported. The majority of all adverse events reported were mild to moderate in severity, with local pain and tenderness being the most common. All adverse events, irrespective of severity, resolved without any sequelae. Subjects who received any of the EBA-175 RII-NG doses had high immunoglobulin G levels which moderately inhibited P . falciparum growth in vitro , compared to those in the placebo group. In conclusion, the EBA-175 RII-NG vaccine was safe, well tolerated and immunogenic in malaria semi-immune Ghanaian adults. Its further development is recommended. The erythrocyte binding antigen region II (EBA-175 RII) is a Plasmodium falciparum ligand that mediates erythrocyte invasion and is considered an important malaria vaccine candidate. A phase Ia trial in malaria naïve adults living in the United States found the recombinant non-glycosylated vaccine antigen, EBA-175 RII-NG adjuvanted with aluminium phosphate to be safe, immunogenic and capable of inducing biologically active antibodies that can inhibit parasite growth in vitro. The aim of the current study was to assess the safety and immunogenicity of this vaccine in malaria exposed semi-immune healthy adults living in a malaria endemic country, Ghana. In this double-blinded, placebo controlled, dose escalation phase I trial, eighteen subjects per group received ascending dose concentrations (5 [mu]g, 20 [mu]g or 80 [mu]g) of the vaccine intramuscularly at 0, 1 and 6 months, while 6 subjects received placebo (normal saline). The primary end point was the number of subjects experiencing Grade 3 systemic or local adverse events within 14 days post-vaccination. Serious adverse events were assessed throughout the study period. Blood samples for immunological analyses were collected at days 0, 14, 28, 42, 180 and 194. A total of 52 subjects received three doses of the vaccine in the respective groups. No serious adverse events were reported. The majority of all adverse events reported were mild to moderate in severity, with local pain and tenderness being the most common. All adverse events, irrespective of severity, resolved without any sequelae. Subjects who received any of the EBA-175 RII-NG doses had high immunoglobulin G levels which moderately inhibited P. falciparum growth in vitro, compared to those in the placebo group. In conclusion, the EBA-175 RII-NG vaccine was safe, well tolerated and immunogenic in malaria semi-immune Ghanaian adults. Its further development is recommended. The erythrocyte binding antigen region II (EBA-175 RII) is a Plasmodium falciparum ligand that mediates erythrocyte invasion and is considered an important malaria vaccine candidate. A phase Ia trial in malaria naïve adults living in the United States found the recombinant non-glycosylated vaccine antigen, EBA-175 RII-NG adjuvanted with aluminium phosphate to be safe, immunogenic and capable of inducing biologically active antibodies that can inhibit parasite growth in vitro . The aim of the current study was to assess the safety and immunogenicity of this vaccine in malaria exposed semi-immune healthy adults living in a malaria endemic country, Ghana. In this double-blinded, placebo controlled, dose escalation phase I trial, eighteen subjects per group received ascending dose concentrations (5 μg, 20 μg or 80 μg) of the vaccine intramuscularly at 0, 1 and 6 months, while 6 subjects received placebo (normal saline). The primary end point was the number of subjects experiencing Grade 3 systemic or local adverse events within 14 days post-vaccination. Serious adverse events were assessed throughout the study period. Blood samples for immunological analyses were collected at days 0, 14, 28, 42, 180 and 194. A total of 52 subjects received three doses of the vaccine in the respective groups. No serious adverse events were reported. The majority of all adverse events reported were mild to moderate in severity, with local pain and tenderness being the most common. All adverse events, irrespective of severity, resolved without any sequelae. Subjects who received any of the EBA-175 RII-NG doses had high immunoglobulin G levels which moderately inhibited P . falciparum growth in vitro , compared to those in the placebo group. In conclusion, the EBA-175 RII-NG vaccine was safe, well tolerated and immunogenic in malaria semi-immune Ghanaian adults. Its further development is recommended. Trial registration ClinicalTrials.gov. Identifier: NCT01026246 The erythrocyte binding antigen region II (EBA-175 RII) is a Plasmodium falciparum ligand that mediates erythrocyte invasion and is considered an important malaria vaccine candidate. A phase Ia trial in malaria naïve adults living in the United States found the recombinant non-glycosylated vaccine antigen, EBA-175 RII-NG adjuvanted with aluminium phosphate to be safe, immunogenic and capable of inducing biologically active antibodies that can inhibit parasite growth in vitro. The aim of the current study was to assess the safety and immunogenicity of this vaccine in malaria exposed semi-immune healthy adults living in a malaria endemic country, Ghana. In this double-blinded, placebo controlled, dose escalation phase I trial, eighteen subjects per group received ascending dose concentrations (5 μg, 20 μg or 80 μg) of the vaccine intramuscularly at 0, 1 and 6 months, while 6 subjects received placebo (normal saline). The primary end point was the number of subjects experiencing Grade 3 systemic or local adverse events within 14 days post-vaccination. Serious adverse events were assessed throughout the study period. Blood samples for immunological analyses were collected at days 0, 14, 28, 42, 180 and 194. A total of 52 subjects received three doses of the vaccine in the respective groups. No serious adverse events were reported. The majority of all adverse events reported were mild to moderate in severity, with local pain and tenderness being the most common. All adverse events, irrespective of severity, resolved without any sequelae. Subjects who received any of the EBA-175 RII-NG doses had high immunoglobulin G levels which moderately inhibited P. falciparum growth in vitro, compared to those in the placebo group. In conclusion, the EBA-175 RII-NG vaccine was safe, well tolerated and immunogenic in malaria semi-immune Ghanaian adults. Its further development is recommended. Trial registration ClinicalTrials.gov. Identifier: NCT01026246 The erythrocyte binding antigen region II (EBA-175 RII) is a Plasmodium falciparum ligand that mediates erythrocyte invasion and is considered an important malaria vaccine candidate. A phase Ia trial in malaria naïve adults living in the United States found the recombinant non-glycosylated vaccine antigen, EBA-175 RII-NG adjuvanted with aluminium phosphate to be safe, immunogenic and capable of inducing biologically active antibodies that can inhibit parasite growth in vitro. The aim of the current study was to assess the safety and immunogenicity of this vaccine in malaria exposed semi-immune healthy adults living in a malaria endemic country, Ghana. In this double-blinded, placebo controlled, dose escalation phase I trial, eighteen subjects per group received ascending dose concentrations (5 [mu]g, 20 [mu]g or 80 [mu]g) of the vaccine intramuscularly at 0, 1 and 6 months, while 6 subjects received placebo (normal saline). The primary end point was the number of subjects experiencing Grade 3 systemic or local adverse events within 14 days post-vaccination. Serious adverse events were assessed throughout the study period. Blood samples for immunological analyses were collected at days 0, 14, 28, 42, 180 and 194. A total of 52 subjects received three doses of the vaccine in the respective groups. No serious adverse events were reported. The majority of all adverse events reported were mild to moderate in severity, with local pain and tenderness being the most common. All adverse events, irrespective of severity, resolved without any sequelae. Subjects who received any of the EBA-175 RII-NG doses had high immunoglobulin G levels which moderately inhibited P. falciparum growth in vitro, compared to those in the placebo group. In conclusion, the EBA-175 RII-NG vaccine was safe, well tolerated and immunogenic in malaria semi-immune Ghanaian adults. Its further development is recommended. Trial registration ClinicalTrials.gov. Identifier: NCT01026246 The erythrocyte binding antigen region II (EBA-175 RII) is a Plasmodium falciparum ligand that mediates erythrocyte invasion and is considered an important malaria vaccine candidate. A phase Ia trial in malaria naïve adults living in the United States found the recombinant non-glycosylated vaccine antigen, EBA-175 RII-NG adjuvanted with aluminium phosphate to be safe, immunogenic and capable of inducing biologically active antibodies that can inhibit parasite growth in vitro. The aim of the current study was to assess the safety and immunogenicity of this vaccine in malaria exposed semi-immune healthy adults living in a malaria endemic country, Ghana. In this double-blinded, placebo controlled, dose escalation phase I trial, eighteen subjects per group received ascending dose concentrations (5 μg, 20 μg or 80 μg) of the vaccine intramuscularly at 0, 1 and 6 months, while 6 subjects received placebo (normal saline). The primary end point was the number of subjects experiencing Grade 3 systemic or local adverse events within 14 days post-vaccination. Serious adverse events were assessed throughout the study period. Blood samples for immunological analyses were collected at days 0, 14, 28, 42, 180 and 194. A total of 52 subjects received three doses of the vaccine in the respective groups. No serious adverse events were reported. The majority of all adverse events reported were mild to moderate in severity, with local pain and tenderness being the most common. All adverse events, irrespective of severity, resolved without any sequelae. Subjects who received any of the EBA-175 RII-NG doses had high immunoglobulin G levels which moderately inhibited P. falciparum growth in vitro, compared to those in the placebo group. In conclusion, the EBA-175 RII-NG vaccine was safe, well tolerated and immunogenic in malaria semi-immune Ghanaian adults. Its further development is recommended.Trial registrationClinicalTrials.gov. Identifier: NCT01026246. The erythrocyte binding antigen region II (EBA-175 RII) is a Plasmodium falciparum ligand that mediates erythrocyte invasion and is considered an important malaria vaccine candidate. A phase Ia trial in malaria naive adults living in the United States found the recombinant non-glycosylated vaccine antigen, EBA-175 RII-NG adjuvanted with aluminium phosphate to be safe, immunogenic and capable of inducing biologically active antibodies that can inhibit parasite growth in vitro. The aim of the current study was to assess the safety and immunogenicity of this vaccine in malaria exposed semi-immune healthy adults living in a malaria endemic country, Ghana. In this double-blinded, placebo controlled, dose escalation phase I trial, eighteen subjects per group received ascending dose concentrations (5 Mg, 20 Mg or 80 Mg) of the vaccine intramuscularly at 0, 1 and 6 months, while 6 subjects received placebo (normal saline). The primary end point was the number of subjects experiencing Grade 3 systemic or local adverse events within 14 days post-vaccination. Serious adverse events were assessed throughout the study period. Blood samples for immunological analyses were collected at days 0, 14, 28, 42, 180 and 194. A total of 52 subjects received three doses of the vaccine in the respective groups. No serious adverse events were reported. The majority of all adverse events reported were mild to moderate in severity, with local pain and tenderness being the most common. All adverse events, irrespective of severity, resolved without any sequelae. Subjects who received any of the EBA-175 RII-NG doses had high immunoglobulin G levels which moderately inhibited P. falciparum growth in vitro, compared to those in the placebo group. In conclusion, the EBA-175 RII-NG vaccine was safe, well tolerated and immunogenic in malaria semi-immune Ghanaian adults. Its further development is recommended. Trial registration ClinicalTrials.gov. Identifier: NCT01026246 The erythrocyte binding antigen region II (EBA-175 RII) is a Plasmodium falciparum ligand that mediates erythrocyte invasion and is considered an important malaria vaccine candidate. A phase Ia trial in malaria naïve adults living in the United States found the recombinant non-glycosylated vaccine antigen, EBA-175 RII-NG adjuvanted with aluminium phosphate to be safe, immunogenic and capable of inducing biologically active antibodies that can inhibit parasite growth in vitro. The aim of the current study was to assess the safety and immunogenicity of this vaccine in malaria exposed semi-immune healthy adults living in a malaria endemic country, Ghana. In this double-blinded, placebo controlled, dose escalation phase I trial, eighteen subjects per group received ascending dose concentrations (5 μg, 20 μg or 80 μg) of the vaccine intramuscularly at 0, 1 and 6 months, while 6 subjects received placebo (normal saline). The primary end point was the number of subjects experiencing Grade 3 systemic or local adverse events within 14 days post-vaccination. Serious adverse events were assessed throughout the study period. Blood samples for immunological analyses were collected at days 0, 14, 28, 42, 180 and 194. A total of 52 subjects received three doses of the vaccine in the respective groups. No serious adverse events were reported. The majority of all adverse events reported were mild to moderate in severity, with local pain and tenderness being the most common. All adverse events, irrespective of severity, resolved without any sequelae. Subjects who received any of the EBA-175 RII-NG doses had high immunoglobulin G levels which moderately inhibited P. falciparum growth in vitro, compared to those in the placebo group. In conclusion, the EBA-175 RII-NG vaccine was safe, well tolerated and immunogenic in malaria semi-immune Ghanaian adults. Its further development is recommended. ClinicalTrials.gov. Identifier: NCT01026246. |
| Audience | Academic |
| Author | Dodoo, Daniel Nkrumah, Francis Abuaku, Benjamin Kronmann, Karl C. Ocran, Josephine Ntiri, Michael Koram, Kwadwo A. Adu, Bright Karikari, Yaa S. Adu-Amankwah, Susan Gyan, Ben |
| AuthorAffiliation | Johns Hopkins Bloomberg School of Public Health, UNITED STATES 1 Department of Epidemiology, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Legon, Ghana 3 US Naval Medical Research Unit 3, Ghana Detachment, Cantonments, Accra, Ghana 2 Department of Immunology, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Legon, Ghana |
| AuthorAffiliation_xml | – name: 1 Department of Epidemiology, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Legon, Ghana – name: 3 US Naval Medical Research Unit 3, Ghana Detachment, Cantonments, Accra, Ghana – name: Johns Hopkins Bloomberg School of Public Health, UNITED STATES – name: 2 Department of Immunology, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Legon, Ghana |
| Author_xml | – sequence: 1 givenname: Kwadwo A. surname: Koram fullname: Koram, Kwadwo A. – sequence: 2 givenname: Bright orcidid: 0000-0002-3622-2137 surname: Adu fullname: Adu, Bright – sequence: 3 givenname: Josephine surname: Ocran fullname: Ocran, Josephine – sequence: 4 givenname: Yaa S. surname: Karikari fullname: Karikari, Yaa S. – sequence: 5 givenname: Susan surname: Adu-Amankwah fullname: Adu-Amankwah, Susan – sequence: 6 givenname: Michael surname: Ntiri fullname: Ntiri, Michael – sequence: 7 givenname: Benjamin surname: Abuaku fullname: Abuaku, Benjamin – sequence: 8 givenname: Daniel surname: Dodoo fullname: Dodoo, Daniel – sequence: 9 givenname: Ben surname: Gyan fullname: Gyan, Ben – sequence: 10 givenname: Karl C. surname: Kronmann fullname: Kronmann, Karl C. – sequence: 11 givenname: Francis surname: Nkrumah fullname: Nkrumah, Francis |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27644034$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNk91u1DAQhSNURH_gDRBYqoRAIkvsJHbSC6TtD2WlQqsWems5zmTXlWOXOEHse_GAzG63VbeqUJWLRJPvHNvHM9vRhvMOoug1TUY0FfTTlR86p-zoGsujhPI04fxZtEXLlMWcJenGve_NaDuEqyTJ04LzF9EmEzzLkjTbiv5eqAb6OVGuJpO2HZyfgjPaYMk35Gh_HFORk_PJJP5-TL4pqzqjyKXS2jgg47o1zoQeOkC16zvVDkEPCNk5MY5cQGvipeuCHWwf9siYnM1UAEI_kkM_VBbifWtcjQZnVmmoPDnw6OStxdKhD2oK5ChoXLk3Hi37oZ6_jJ43ygZ4tXrvRD-_HP04-BqfnB5PDsYnsRYl7eMcmoqBymstaAmaZ5orwdM0q0TVgGYF04KXQgmgjWqysmKNprqu0zyHqoAi3Yne3vheWx_kKvAgacFoUoqMMSQmN0Tt1ZW87kyrurn0yshlwXdTqbreaAuSVzkva-AlxexrlpaqyLMmz1LOVV0Iil6fV6sNVQu1hkWgds10_Y8zMzn1v2WesIIygQbvVwad_zVA6GVrggZrlQM_LPeNufAS13wCyuiifVJEdx-gjwexoqYKz2pc43GLemEqx5mgRZnkBUdq9AiFT42dorGRG4P1NcGHNQEyPfzpp2oIQU4uzp_Onl6us-_usTNQtp8Fb4dFj4V18M39S7m7jdsJQiC7AXTnQ-iguUNoIheDehuXXAyqXA0qyvYeyHDmli2OiRj7f_E_DAtDaw |
| CitedBy_id | crossref_primary_10_21769_BioProtoc_3743 crossref_primary_10_1021_acsomega_3c05323 crossref_primary_10_1016_j_pt_2022_09_005 crossref_primary_10_1016_j_vaccine_2025_126952 crossref_primary_10_1038_s41598_020_67877_8 crossref_primary_10_24267_23897325_428 crossref_primary_10_3389_fmicb_2019_02712 crossref_primary_10_1016_j_jmb_2019_05_018 crossref_primary_10_3390_vaccines9020115 crossref_primary_10_1093_femsre_fuz005 crossref_primary_10_1038_s41467_022_30605_z crossref_primary_10_3389_fimmu_2021_690348 crossref_primary_10_1038_s41467_022_31640_6 crossref_primary_10_1016_j_meegid_2022_105397 crossref_primary_10_24267_23897325_348 crossref_primary_10_3390_biom14010100 crossref_primary_10_1371_journal_ppat_1012638 |
| Cites_doi | 10.1016/j.vaccine.2007.10.064 10.1371/journal.pmed.1000398 10.1073/pnas.1104050108 10.1086/317933 10.1371/journal.pone.0003960 10.1016/j.vaccine.2014.03.020 10.1128/IAI.00960-09 10.1093/cid/civ525 10.1182/blood.V67.5.1519.1519 10.1016/j.vaccine.2010.02.024 10.1056/NEJMoa1207564 10.1016/j.vaccine.2006.05.090 10.1371/journal.pone.0001563 10.1073/pnas.89.15.7085 10.1074/jbc.M113.484840 10.1371/journal.pmed.1000406 10.1371/journal.pone.0007549 10.1126/science.3901257 10.1016/j.vaccine.2009.03.014 10.1128/CVI.05523-11 10.1016/S0140-6736(05)67669-6 10.1016/j.vaccine.2009.09.011 10.1084/jem.193.12.1403 10.1371/journal.pone.0009041 10.1128/CVI.00082-10 10.1371/journal.pone.0008787 10.1371/journal.pone.0073624 10.1172/JCI113178 10.1016/j.vaccine.2009.10.087 10.1111/j.1365-3024.2009.01193.x 10.1128/IAI.05961-11 10.1371/journal.pone.0022525 10.1126/science.8009226 10.1186/1475-2875-8-163 10.1371/journal.pone.0001045 10.1093/infdis/jiu219 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2016 Public Library of Science This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication: https://creativecommons.org/publicdomain/zero/1.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: COPYRIGHT 2016 Public Library of Science – notice: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication: https://creativecommons.org/publicdomain/zero/1.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM IOV ISR 3V. 7QG 7QL 7QO 7RV 7SN 7SS 7T5 7TG 7TM 7U9 7X2 7X7 7XB 88E 8AO 8C1 8FD 8FE 8FG 8FH 8FI 8FJ 8FK ABJCF ABUWG AEUYN AFKRA ARAPS ATCPS AZQEC BBNVY BENPR BGLVJ BHPHI C1K CCPQU D1I DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. KB. KB0 KL. L6V LK8 M0K M0S M1P M7N M7P M7S NAPCQ P5Z P62 P64 PATMY PDBOC PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PTHSS PYCSY RC3 7X8 F1W H95 H97 L.G 5PM DOA |
| DOI | 10.1371/journal.pone.0163066 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Opposing Viewpoints Gale In Context: Science ProQuest Central (Corporate) Animal Behavior Abstracts Bacteriology Abstracts (Microbiology B) Biotechnology Research Abstracts Nursing & Allied Health Database Ecology Abstracts Entomology Abstracts (Full archive) Immunology Abstracts Meteorological & Geoastrophysical Abstracts Nucleic Acids Abstracts Virology and AIDS Abstracts Agricultural Science Collection Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Materials Science & Engineering Collection ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland Advanced Technologies & Aerospace Collection ProQuest Agricultural & Environmental Science Database ProQuest Central Essentials - QC Biological Science Collection ProQuest Central Technology Collection Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Materials Science Collection ProQuest Central Korea Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Materials Science Database Nursing & Allied Health Database (Alumni Edition) Meteorological & Geoastrophysical Abstracts - Academic ProQuest Engineering Collection Biological Sciences Agricultural Science Database ProQuest Health & Medical Collection Medical Database (ProQuest) Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Engineering Database Nursing & Allied Health Premium Advanced Technologies & Aerospace Database ProQuest Advanced Technologies & Aerospace Collection Biotechnology and BioEngineering Abstracts Environmental Science Database Materials Science Collection ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China Engineering Collection Environmental Science Collection Genetics Abstracts MEDLINE - Academic ASFA: Aquatic Sciences and Fisheries Abstracts Aquatic Science & Fisheries Abstracts (ASFA) 1: Biological Sciences & Living Resources Aquatic Science & Fisheries Abstracts (ASFA) 3: Aquatic Pollution & Environmental Quality Aquatic Science & Fisheries Abstracts (ASFA) Professional PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Agricultural Science Database Publicly Available Content Database ProQuest Central Student ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Meteorological & Geoastrophysical Abstracts Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Engineering Collection Advanced Technologies & Aerospace Collection Engineering Database Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition Agricultural Science Collection ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database Ecology Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Environmental Science Collection Entomology Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Environmental Science Database ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic Meteorological & Geoastrophysical Abstracts - Academic ProQuest One Academic (New) Technology Collection Technology Research Database ProQuest One Academic Middle East (New) Materials Science Collection ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Genetics Abstracts ProQuest Engineering Collection Biotechnology Research Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Agricultural & Environmental Science Collection AIDS and Cancer Research Abstracts Materials Science Database ProQuest Materials Science Collection ProQuest Public Health ProQuest Nursing & Allied Health Source ProQuest SciTech Collection Advanced Technologies & Aerospace Database ProQuest Medical Library Animal Behavior Abstracts Materials Science & Engineering Collection Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic Aquatic Science & Fisheries Abstracts (ASFA) Professional ASFA: Aquatic Sciences and Fisheries Abstracts Aquatic Science & Fisheries Abstracts (ASFA) 1: Biological Sciences & Living Resources Aquatic Science & Fisheries Abstracts (ASFA) 3: Aquatic Pollution & Environmental Quality |
| DatabaseTitleList | MEDLINE - Academic Agricultural Science Database Aquatic Science & Fisheries Abstracts (ASFA) Professional MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: 8FG name: ProQuest Technology Collection url: https://search.proquest.com/technologycollection1 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Sciences (General) |
| DocumentTitleAlternate | EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly in Semi-Immune Adults |
| EISSN | 1932-6203 |
| ExternalDocumentID | 1821097422 oai_doaj_org_article_6b569de691644d239a854f54366ad871 PMC5028127 4187418181 A471890586 27644034 10_1371_journal_pone_0163066 |
| Genre | Randomized Controlled Trial Journal Article |
| GeographicLocations | United States--US Ghana USA |
| GeographicLocations_xml | – name: United States--US – name: Ghana – name: USA |
| GrantInformation_xml | – fundername: NIAID NIH HHS grantid: N01 AI005421 – fundername: NIAID NIH HHS grantid: HHSN266200400016C – fundername: ; grantid: HHSN266200400016C |
| GroupedDBID | --- 123 29O 2WC 53G 5VS 7RV 7X2 7X7 7XC 88E 8AO 8C1 8CJ 8FE 8FG 8FH 8FI 8FJ A8Z AAFWJ AAUCC AAWOE AAYXX ABDBF ABIVO ABJCF ABUWG ACGFO ACIHN ACIWK ACPRK ACUHS ADBBV ADRAZ AEAQA AENEX AEUYN AFKRA AFPKN AFRAH AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS APEBS ARAPS ATCPS BAWUL BBNVY BCNDV BENPR BGLVJ BHPHI BKEYQ BPHCQ BVXVI BWKFM CCPQU CITATION CS3 D1I D1J D1K DIK DU5 E3Z EAP EAS EBD EMOBN ESX EX3 F5P FPL FYUFA GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE IAO IEA IGS IHR IHW INH INR IOV IPY ISE ISR ITC K6- KB. KQ8 L6V LK5 LK8 M0K M1P M48 M7P M7R M7S M~E NAPCQ O5R O5S OK1 OVT P2P P62 PATMY PDBOC PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO PTHSS PV9 PYCSY RNS RPM RZL SV3 TR2 UKHRP WOQ WOW ~02 ~KM CGR CUY CVF ECM EIF IPNFZ NPM PJZUB PPXIY PQGLB RIG BBORY PMFND 3V. 7QG 7QL 7QO 7SN 7SS 7T5 7TG 7TM 7U9 7XB 8FD 8FK AZQEC C1K DWQXO FR3 GNUQQ H94 K9. KL. M7N P64 PKEHL PQEST PQUKI PRINS RC3 7X8 PUEGO ESTFP F1W H95 H97 L.G 5PM AAPBV ABPTK N95 |
| ID | FETCH-LOGICAL-c791t-5efb2ea5dc719ec64c6a76334b7bfec282c7697a7e1faf49b2fc1cdd355eb8e83 |
| IEDL.DBID | 8FG |
| ISSN | 1932-6203 |
| IngestDate | Sun May 07 16:28:29 EDT 2023 Wed Aug 27 01:02:33 EDT 2025 Thu Aug 21 14:12:52 EDT 2025 Mon Sep 08 04:59:31 EDT 2025 Thu Sep 04 18:30:53 EDT 2025 Fri Jul 25 10:24:43 EDT 2025 Tue Jun 17 21:12:00 EDT 2025 Tue Jun 10 20:36:13 EDT 2025 Fri Jun 27 04:43:16 EDT 2025 Fri Jun 27 04:59:26 EDT 2025 Thu May 22 21:21:53 EDT 2025 Mon Jul 21 06:01:35 EDT 2025 Tue Jul 01 02:18:39 EDT 2025 Thu Apr 24 22:51:39 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9 |
| Language | English |
| License | This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication. Creative Commons CC0 public domain |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c791t-5efb2ea5dc719ec64c6a76334b7bfec282c7697a7e1faf49b2fc1cdd355eb8e83 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 Current address: Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America Current address: Naval Medical Center, Portsmouth, Virginia, United States of America Competing Interests: The product developed in this study is owned by DMID /NIAID. Leidos was a contract manufacturer and has no commercial interests whatsoever after delivering the product to DMID/NIAID. Leidos had no part in the design, conduct, analysis or interpretation of data from the study. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials. Conceptualization: KAK FN JO. Data curation: KAK JO YSK DD BG B. Abuaku. Formal analysis: KAK B. Adu DD. Funding acquisition: KAK FN. Investigation: KAK B. Adu JO YSA SAA MN B. Abuaku DD BG KCK FN. Methodology: KAK JO DD. Project administration: KAK SAA FN. Resources: KAK MN B. Abuaku KCK. Supervision: KAK DD FN. Validation: KAK DD. Visualization: KAK B. Adu. Writing – original draft: KAK B. Adu JO. Writing – review & editing: KAK B. Adu. Current address: John H Stroger Jr Hospital of Cook County, Chicago, Illinois, United States of America |
| ORCID | 0000-0002-3622-2137 |
| OpenAccessLink | https://www.proquest.com/docview/1821097422?pq-origsite=%requestingapplication% |
| PMID | 27644034 |
| PQID | 1821097422 |
| PQPubID | 1436336 |
| PageCount | e0163066 |
| ParticipantIDs | plos_journals_1821097422 doaj_primary_oai_doaj_org_article_6b569de691644d239a854f54366ad871 pubmedcentral_primary_oai_pubmedcentral_nih_gov_5028127 proquest_miscellaneous_1827916954 proquest_miscellaneous_1822119323 proquest_journals_1821097422 gale_infotracmisc_A471890586 gale_infotracacademiconefile_A471890586 gale_incontextgauss_ISR_A471890586 gale_incontextgauss_IOV_A471890586 gale_healthsolutions_A471890586 pubmed_primary_27644034 crossref_primary_10_1371_journal_pone_0163066 crossref_citationtrail_10_1371_journal_pone_0163066 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2016-09-19 |
| PublicationDateYYYYMMDD | 2016-09-19 |
| PublicationDate_xml | – month: 09 year: 2016 text: 2016-09-19 day: 19 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: San Francisco – name: San Francisco, CA USA |
| PublicationTitle | PloS one |
| PublicationTitleAlternate | PLoS One |
| PublicationYear | 2016 |
| Publisher | Public Library of Science Public Library of Science (PLoS) |
| Publisher_xml | – name: Public Library of Science – name: Public Library of Science (PLoS) |
| References | L Jiang (ref22) 2011; 108 KA Koram (ref39) 2007; 41 M Roestenberg (ref11) 2008; 3 RA O'Donnell (ref29) 2001; 193 TJ Hadley (ref20) 1987; 80 OJ Akpogheneta (ref32) 2010; 32 RD Ellis (ref37) 2010; 5 (ref3) 2011; 8 S Belard (ref15) 2011; 6 SB Sirima (ref7) 2007; 25 C Dobano (ref33) 2012; 19 D Camus (ref23) 1985; 230 (ref2) 2015 PL Alonso (ref4) 2011; 8 I Sagara (ref12) 2009; 27 HM El Sahly (ref27) 2010; 17 (ref1) 2015 PD Crompton (ref35) 2010; 78 GH Mitchell (ref21) 1986; 67 A Dicko (ref10) 2008; 3 TR Jones (ref26) 2001; 183 M Esen (ref5) 2009; 27 MA Thera (ref14) 2010; 5 V Irani (ref36) 2015; 61 JT Bruder (ref38) 2010; 28 JP Lusingu (ref6) 2009; 8 G Moncunill (ref31) 2013; 8 SB Sirima (ref8) 2009; 4 EH Clark (ref30) 2012; 80 MT White (ref34) 2014; 210 PL Alonso (ref16) 2005; 366 M Theisen (ref18) 2014; 32 BK Sim (ref19) 1994; 264 JH Adams (ref24) 1992; 89 K Miura (ref28) 2008; 26 A Dicko (ref9) 2007; 2 M Wanaguru (ref25) 2013; 288 A Olotu (ref17) 2013; 368 I Sagara (ref13) 2009; 27 |
| References_xml | – volume: 26 start-page: 193 issue: 2 year: 2008 ident: ref28 article-title: Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines publication-title: Vaccine doi: 10.1016/j.vaccine.2007.10.064 – volume: 8 start-page: e1000398 issue: 1 year: 2011 ident: ref3 article-title: A research agenda for malaria eradication: vaccines publication-title: PLoS Med doi: 10.1371/journal.pmed.1000398 – volume: 108 start-page: 7553 issue: 18 year: 2011 ident: ref22 article-title: Evidence for erythrocyte-binding antigen 175 as a component of a ligand-blocking blood-stage malaria vaccine publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1104050108 – volume: 183 start-page: 303 issue: 2 year: 2001 ident: ref26 article-title: Protection of Aotus monkeys by Plasmodium falciparum EBA-175 region II DNA prime-protein boost immunization regimen publication-title: J Infect Dis doi: 10.1086/317933 – volume: 3 start-page: e3960 issue: 12 year: 2008 ident: ref11 article-title: Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02 publication-title: PLoS One doi: 10.1371/journal.pone.0003960 – volume: 32 start-page: 2623 issue: 22 year: 2014 ident: ref18 article-title: A multi-stage malaria vaccine candidate targeting both transmission and asexual parasite life-cycle stages publication-title: Vaccine doi: 10.1016/j.vaccine.2014.03.020 – year: 2015 ident: ref2 article-title: Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial publication-title: Lancet – volume: 78 start-page: 737 issue: 2 year: 2010 ident: ref35 article-title: In vitro growth-inhibitory activity and malaria risk in a cohort study in mali publication-title: Infect Immun doi: 10.1128/IAI.00960-09 – volume: 61 start-page: 1244 issue: 8 year: 2015 ident: ref36 article-title: Acquisition of Functional Antibodies That Block the Binding of Erythrocyte-Binding Antigen 175 and Protection Against Plasmodium falciparum Malaria in Children publication-title: Clin Infect Dis doi: 10.1093/cid/civ525 – volume: 67 start-page: 1519 issue: 5 year: 1986 ident: ref21 article-title: Invasion of erythrocytes by Plasmodium falciparum malaria parasites: evidence for receptor heterogeneity and two receptors publication-title: Blood doi: 10.1182/blood.V67.5.1519.1519 – volume: 28 start-page: 3201 issue: 18 year: 2010 ident: ref38 article-title: Adenovectors induce functional antibodies capable of potent inhibition of blood stage malaria parasite growth publication-title: Vaccine doi: 10.1016/j.vaccine.2010.02.024 – volume: 368 start-page: 1111 issue: 12 year: 2013 ident: ref17 article-title: Four-year efficacy of RTS,S/AS01E and its interaction with malaria exposure publication-title: N Engl J Med doi: 10.1056/NEJMoa1207564 – volume: 25 start-page: 2723 issue: 14 year: 2007 ident: ref7 article-title: Safety and immunogenicity of the Plasmodium falciparum merozoite surface protein-3 long synthetic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa publication-title: Vaccine doi: 10.1016/j.vaccine.2006.05.090 – volume: 3 start-page: e1563 issue: 2 year: 2008 ident: ref10 article-title: Phase 1 study of a combination AMA1 blood stage malaria vaccine in Malian children publication-title: PLoS One doi: 10.1371/journal.pone.0001563 – volume: 89 start-page: 7085 issue: 15 year: 1992 ident: ref24 article-title: A family of erythrocyte binding proteins of malaria parasites publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.89.15.7085 – volume: 288 start-page: 32106 issue: 45 year: 2013 ident: ref25 article-title: Biochemical analysis of the Plasmodium falciparum erythrocyte-binding antigen-175 (EBA175)-glycophorin-A interaction: implications for vaccine design publication-title: J Biol Chem doi: 10.1074/jbc.M113.484840 – volume: 8 start-page: e1000406 issue: 1 year: 2011 ident: ref4 article-title: A research agenda to underpin malaria eradication publication-title: PLoS Med doi: 10.1371/journal.pmed.1000406 – volume: 4 start-page: e7549 issue: 10 year: 2009 ident: ref8 article-title: Safety and immunogenicity of the malaria vaccine candidate MSP3 long synthetic peptide in 12–24 months-old Burkinabe children publication-title: PLoS One doi: 10.1371/journal.pone.0007549 – volume: 230 start-page: 553 issue: 4725 year: 1985 ident: ref23 article-title: A Plasmodium falciparum antigen that binds to host erythrocytes and merozoites publication-title: Science doi: 10.1126/science.3901257 – volume: 27 start-page: 3090 issue: 23 year: 2009 ident: ref12 article-title: A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali publication-title: Vaccine doi: 10.1016/j.vaccine.2009.03.014 – volume: 19 start-page: 157 issue: 2 year: 2012 ident: ref33 article-title: Age-dependent IgG subclass responses to Plasmodium falciparum EBA-175 are differentially associated with incidence of malaria in Mozambican children publication-title: Clin Vaccine Immunol doi: 10.1128/CVI.05523-11 – volume: 366 start-page: 2012 issue: 9502 year: 2005 ident: ref16 article-title: Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(05)67669-6 – year: 2015 ident: ref1 – volume: 27 start-page: 6862 issue: 49 year: 2009 ident: ref5 article-title: Safety and immunogenicity of GMZ2—a MSP3-GLURP fusion protein malaria vaccine candidate publication-title: Vaccine doi: 10.1016/j.vaccine.2009.09.011 – volume: 193 start-page: 1403 issue: 12 year: 2001 ident: ref29 article-title: Antibodies against merozoite surface protein (MSP)-1(19) are a major component of the invasion-inhibitory response in individuals immune to malaria publication-title: J Exp Med doi: 10.1084/jem.193.12.1403 – volume: 5 start-page: e9041 issue: 2 year: 2010 ident: ref14 article-title: Safety and immunogenicity of an AMA1 malaria vaccine in Malian children: results of a phase 1 randomized controlled trial publication-title: PLoS One doi: 10.1371/journal.pone.0009041 – volume: 17 start-page: 1552 issue: 10 year: 2010 ident: ref27 article-title: Safety and immunogenicity of a recombinant nonglycosylated erythrocyte binding antigen 175 Region II malaria vaccine in healthy adults living in an area where malaria is not endemic publication-title: Clin Vaccine Immunol doi: 10.1128/CVI.00082-10 – volume: 41 start-page: 160 issue: 4 year: 2007 ident: ref39 article-title: Population based reference intervals for common blood haematological and biochemical parameters in the Akuapem North district publication-title: Ghana Med J – volume: 5 start-page: e8787 issue: 1 year: 2010 ident: ref37 article-title: Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naive adults publication-title: PLoS One doi: 10.1371/journal.pone.0008787 – volume: 8 start-page: e73624 issue: 8 year: 2013 ident: ref31 article-title: High antibody responses against Plasmodium falciparum in immigrants after extended periods of interrupted exposure to malaria publication-title: PLoS One doi: 10.1371/journal.pone.0073624 – volume: 80 start-page: 1190 issue: 4 year: 1987 ident: ref20 article-title: Falciparum malaria parasites invade erythrocytes that lack glycophorin A and B (MkMk). Strain differences indicate receptor heterogeneity and two pathways for invasion publication-title: J Clin Invest doi: 10.1172/JCI113178 – volume: 27 start-page: 7292 issue: 52 year: 2009 ident: ref13 article-title: A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults publication-title: Vaccine doi: 10.1016/j.vaccine.2009.10.087 – volume: 32 start-page: 296 issue: 4 year: 2010 ident: ref32 article-title: Boosting antibody responses to Plasmodium falciparum merozoite antigens in children with highly seasonal exposure to infection publication-title: Parasite Immunol doi: 10.1111/j.1365-3024.2009.01193.x – volume: 80 start-page: 1583 issue: 4 year: 2012 ident: ref30 article-title: Plasmodium falciparum malaria in the Peruvian Amazon, a region of low transmission, is associated with immunologic memory publication-title: Infect Immun doi: 10.1128/IAI.05961-11 – volume: 6 start-page: e22525 issue: 7 year: 2011 ident: ref15 article-title: A randomized controlled phase Ib trial of the malaria vaccine candidate GMZ2 in African children publication-title: PLoS One doi: 10.1371/journal.pone.0022525 – volume: 264 start-page: 1941 issue: 5167 year: 1994 ident: ref19 article-title: Receptor and ligand domains for invasion of erythrocytes by Plasmodium falciparum publication-title: Science doi: 10.1126/science.8009226 – volume: 8 start-page: 163 year: 2009 ident: ref6 article-title: Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12–24 months publication-title: Malar J doi: 10.1186/1475-2875-8-163 – volume: 2 start-page: e1045 issue: 10 year: 2007 ident: ref9 article-title: Impact of a Plasmodium falciparum AMA1 vaccine on antibody responses in adult Malians publication-title: PLoS One doi: 10.1371/journal.pone.0001045 – volume: 210 start-page: 1115 issue: 7 year: 2014 ident: ref34 article-title: Dynamics of the antibody response to Plasmodium falciparum infection in African children publication-title: J Infect Dis doi: 10.1093/infdis/jiu219 |
| SSID | ssj0053866 |
| Score | 2.3019083 |
| Snippet | The erythrocyte binding antigen region II (EBA-175 RII) is a Plasmodium falciparum ligand that mediates erythrocyte invasion and is considered an important... The erythrocyte binding antigen region II (EBA-175 RII) is a Plasmodium falciparum ligand that mediates erythrocyte invasion and is considered an important... |
| SourceID | plos doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | e0163066 |
| SubjectTerms | Acids Adult Adults Aluminum Aluminum phosphate Analysis Antibodies Antigens Biological activity Biology and Life Sciences Clinical trials Complications Dosage Dose-Response Relationship, Immunologic Double-Blind Method Epidemiology Erythrocytes Health care Health sciences Humans Immunogenicity Immunoglobulin G Immunoglobulins Immunology Infections Injections, Intramuscular Ligands Malaria Malaria vaccines Malaria Vaccines - administration & dosage Malaria Vaccines - adverse effects Malaria Vaccines - immunology Medical research Medicine and Health Sciences Pain Parasites Phosphates Placebos Plasmodium falciparum Research and Analysis Methods Safety Vaccination Vaccines Vector-borne diseases |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1db9MwFLVQn3hBjK8VBhiEBEh4S2LHcXhrR8eKxJg2Nu0tsh2bVcqSirQP_V_8QO5N0mpBE-OB1_okTX2vr4-b42NC3iSxDnyuJFNKcyZCI5gJo5wFRvpA4SEceSOQPZKHZ-LLRXxx7agv1IS19sBtx-1JE8s0dxJojBB5xFOtYuFjwaXUuWp2j0dBGqwXU20NhlEsZbdRjifhXheX3XlVul0gOcCTZW8iavz6N1V5MC-q-ibK-ady8tpUdHCf3Os4JB21z75F7rjyAdnqRmlN33VW0u8fkl-n2rvFiuoyp1PcCVJBvswsMG9aeToZjxjM6_RkOmVHn-lXDavcmabn2uLbdrr21cXTPOkUn-Rq2cpWixWdlfTUXc1Yc1fELotF_ZGO6PElzIs0_ECBmpvCsXGBhow5Pcb_601F91ttfAEffapQ1UYnNeRJkyAUVY2rR-TsYPJ9_5B15zQwm6ThgsXOm8jpOLdJmDorhZUayhYXJjHeWVjU2USmiU5c6LUXqYm8DW2eA9VxRjnFH5NBCZHZJlSFPE5hxgQeqYTwXtnAGmUF9wKYpvZDwtdBy2xnYo5naRRZ82YugcVMG4MMQ511oR4Strlq3pp43IIfYz5ssGjB3XwAiZl1iZndlphD8hKzKWv3s24KSTZCOpAGsYKved0g0IajRJ3PD72s62z67fwfQKcnPdDbDuQr6A6ru70V8JvQ3quH3OkhoZjYXvM25v66V-oMlp-oURBRBFeux8PNza82zXhT1O6Vrlo2GLQR5BH_KwZSSaaxGJIn7RDb9H6UQAcHHFqS3uDrhaffUs4uG6f0GNhzGCVP_0c8n5G7QJYlaoXCdIcMFj-X7jkQ0oV50dSe35h6iHM priority: 102 providerName: Directory of Open Access Journals – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3rb9MwELdG-cIXxHitY4BBSIBEqjwcJ0FCqB0dK9LGtLJp3yLbsbdKWVKaVqL_F38gd3mJoDL4Gp_zuIfvd_H5jpBXgS9sk4TcCkPhWcyRzJKOm1i25MYOsQlHUibIHvPDM_blwr_YIk3P1pqBxcbQDvtJnS3SwY_v649g8B_Krg2B00wazPNMDwDCAArmt8ht8E0cw7Ej1u4rgHVzXh-g-9vMjoMq6_i3q3VvnubFJij6Z0blby7q4B65W2NLOqyUYZts6ew-2a6tt6Bv6hLTbx-Qn1Nh9HJNRZbQCZ4QyUGPZgoQOc0NHY-GFvh7ejqZWMef6ZEAFs0EPRcKd-FpU28Xu3zSCb7J9apKZ03XdJbRqb6eWeVdkXaVLov3dEhPrsBfUucdBcguU22NUizUmNAT_I8vc7pf5cyncOlTjtludFyA_pSKQzHbcf2QnB2Mv-0fWnX_BksFkbO0fG2kq4WfqMCJtOJMcQHLmcdkII1WEOypgEeBCLRjhGGRdI1yVJIABNIy1KH3iPQykMwOoaHj-RF4UsCXIWPGhMpWMlTMMwwQqDB94jVCi1Vd3Bx7bKRxuWMXQJBTySBGUce1qPvEamfNq-Ie_6AfoT60tFiau7yQLy7j2tJjLn0eJZoD7mYscb1IhD4zPvM4FwmEp33yHLUprs65tgtMPESYENl-CI95WVJgeY4M838uxaoo4snX8_8gmp52iF7XRCYHdihRn7mAb8KyXx3KvQ4lLDKqM7yDut9wpYghLMXcBea6MLOxh83DL9phvCnm9GU6X5U0WF7Qc70baUCVeOSzPnlcmVjLfTcABtsejAQd4-uIpzuSza7KCuo-oGrHDXZvfvUn5A7AY47ZQU60R3rLxUo_BQi6lM_KVeUX2MKG-w priority: 102 providerName: Scholars Portal |
| Title | Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly in Semi-Immune Adults: A Phase 1, Double-Blinded Placebo Controlled Dosage Escalation Study |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/27644034 https://www.proquest.com/docview/1821097422 https://www.proquest.com/docview/1822119323 https://www.proquest.com/docview/1827916954 https://pubmed.ncbi.nlm.nih.gov/PMC5028127 https://doaj.org/article/6b569de691644d239a854f54366ad871 http://dx.doi.org/10.1371/journal.pone.0163066 |
| Volume | 11 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3Nb9MwFLfYduGCGF_rGMUgJEAiW5M4tsMFtaPbirQxbWzqLXIce6uUJWVpD7vwV_EH8l7iFoKmwcWH-OXL7-tn-_k9Qt6ISPVsJrknpQo95qfMS_0g83optz2JRTiyOkD2iB-csS_jaOwW3CoXVrmwibWhzkqNa-Q7gINxs5QFwafpdw-rRuHuqiuhsULWfPA0KOdyb39hiUGXOXfH5ULh7zjubE_LwmwD1AG0zFvuqM7av7TNq9O8rG4Dnn_HT_7hkPYekgcOSdJ-w_p1cs8Uj8i609WKvnMJpd8_Jj9PlTWzG6qKjI7wPEgJUjPRgL9paelw0PfAu9OT0cg72qeHCua6E0XPlcY9d7rIros1PekIv-Rq3gSv5jd0UtBTczXx6qci7TyfVR9pnx5fgnek_gcKAD3NjTfIMS1jRo9x1T4t6W4TIZ_Dpc8lxrbRYQXSUosJxdjGmyfkbG_4bffAc9UaPC1if-ZFxqaBUVGmhR8bzZnmCoxXyFKRWqNhaqcFj4USxrfKsjgNrPZ1lgHgMak0MnxKVgvgzAah0g-jGPwmoEnJmLVS93QqNQstA7ypbIeEC6Yl2qUyx4oaeVLvzwmY0jQ8SJDViWN1h3jLu6ZNKo9_0A9QHpa0mIi7vlBeXyROrxOeRjzODAeUzVgWhLGSEbMRCzlXGUxGO-QlSlPSnGpdmpOkj6Ag7kUSXvO6psBkHAVG-1yoeVUlo6_n_0F0etIieuuIbAnDoZU7YQH_hEm-WpRbLUowKbrVvYGyvxiVKvmtfHDnQh9u73617MaHYgRfYcp5TYPJBMMgvJMGRInHEeuQZ42KLUc_EDDAvRB6REv5Wuxp9xSTyzpfegQY2g_E5t2f_pzcBzDMMRbIj7fI6ux6bl4A4JylXbIixgJauet3awvTJWuD4dHxSbdewoH2kElsfwx_AYlJh2k |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Zb9QwELZKeYAXRLm6UKhBIEAi7SZx7AQJoe1FQw-qXupbcBy7XSlNlmZXaP8UT_xAZnJBUFV46Ws8cRLP9U08niHkpfBk3yQ-t3xfuhazY2bFtpNY_Zibvo9NOJIyQXaXbx6xzyfeyQz50ZyFwbTKxiaWhjrJFf4jXwYcjJulzHE-jr5Z2DUKd1ebFhqVWGzp6XcI2YoP4Rrw95XjbKwfrm5adVcBS4nAHlueNrGjpZcoYQdacaa4BCVzWSxioxWEIErwQEihbSMNC2LHKFslCThmHfvad2HeG-Qmwz_joD_ipA3wwHZwXh_Pc4W9XEvD0ijP9BJAK0DnvOP-yi4BrS-YHaV5cRnQ_Ttf8w8HuHGX3KmRKx1UojZHZnR2j8zVtqGgb-oC1m_vk58H0ujxlMosoSGeP8lBSocK8D7NDV1fGViAJuh-GFq7n-iOhNh6KOmxVLjHT5tqvthDlIb4JueTKlk2ndJhRg_0-dAqZ0XaSTou3tMB3TsDb0ztdxQCgjjV1kqKZSATuoe7BHFOV6uM_BQureWYS0fXC5DOUiwp5lJOH5Cja-HjQzKbAWfmCfVt1wvATwN69Rkzxld9FfuKuYYBvpWmR9yGaZGqS6djB480KvcDBYRQFQ8iZHVUs7pHrPauUVU65B_0KygPLS0W_i4v5BenUW1HIh57PEg0B1TPWOK4gfQ9Zjzmci4TCH57ZBGlKapO0bbmKxogCAn6ng-PeVFSYPGPDLOLTuWkKKLwy_F_EB3sd4he10Qmh-VQsj7RAd-ERcU6lAsdSjBhqjM8j7LfrEoR_VZ2uLPRh8uHn7fDOClmDGY6n5Q0WLzQddwraUCUeOCxHnlUqVi7-o6ABe67MCI6ytdhT3ckG56V9dk9wOy2Ix5f_eqL5Nbm4c52tB3ubj0htwGIc8xDsoMFMju-mOinAHbH8bPSwlDy9bpN2i8ngcCO |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKkRAXRHl1oVCDQIDUtJvEsRMkhLYvGgpl1dKqt-A4drtSmizNrtD-L078OmbygqCqcOk1njiJ5_VNPJ4h5LnwZN8kPrd8X7oWs2NmxbaTWP2Ym76PTTiSMkF2j-8csg_H3vEc-dmchcG0ysYmloY6yRX-I18DHIybpcxx1kydFjHc3H43_mZhByncaW3aaVQisqtn3yF8K96Gm8DrF46zvfVlY8eqOwxYSgT2xPK0iR0tvUQJO9CKM8UlKJzLYhEbrSAcUYIHQgptG2lYEDtG2SpJwEnr2Ne-C_NeI9eFC6gKdEkct8Ee2BHO66N6rrDXaslYHeeZXgWYBUidd1xh2TGg9Qvz4zQvLgK9f-du_uEMt2-TWzWKpYNK7BbInM7ukIXaThT0VV3M-vVd8uNAGj2ZUZklNMSzKDlI7EgB9qe5oVvrAwuQBd0PQ2vvPf0kIc4eSXokFe7306ayL_YTpSG-ydm0SpxNZ3SU0QN9NrLKWZF2mk6KN3RAh6fgmam9QiE4iFNtradYEjKhQ9wxiHO6UWXnp3BpM8e8OrpVgKSWIkoxr3J2jxxeCR_vk_kMOLNIqG-7XgA-G5Csz5gxvuqr2FfMNQywrjQ94jZMi1RdRh27eaRRuTcoIJyqeBAhq6Oa1T1itXeNqzIi_6BfR3loabEIeHkhPz-JapsS8djjQaI5IHzGEscNpO8x4zGXc5lAINwjyyhNUXWitjVl0QABSdD3fHjMs5ICC4FkqFIncloUUfj56D-IDvY7RC9rIpPDcihZn-6Ab8ICYx3KpQ4lmDPVGV5E2W9WpYh-Kz7c2ejDxcNP22GcFLMHM51PSxosZOg67qU0IEo88FiPPKhUrF19R8AC910YER3l67CnO5KNTsta7R7gd9sRDy9_9WVyA4xZ9DHc231EbgIm55iSZAdLZH5yPtWPAfdO4ielgaHk61VbtF9PZMTN |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Safety+and+Immunogenicity+of+EBA-175+RII-NG+Malaria+Vaccine+Administered+Intramuscularly+in+Semi-Immune+Adults%3A+A+Phase+1%2C+Double-Blinded+Placebo+Controlled+Dosage+Escalation+Study&rft.jtitle=PloS+one&rft.au=Koram%2C+Kwadwo+A&rft.au=Bright+Adu&rft.au=Ocran%2C+Josephine&rft.au=Karikari%2C+Yaa+S&rft.date=2016-09-19&rft.pub=Public+Library+of+Science&rft.eissn=1932-6203&rft.volume=11&rft.issue=9&rft.spage=e0163066&rft_id=info:doi/10.1371%2Fjournal.pone.0163066&rft.externalDBID=HAS_PDF_LINK&rft.externalDocID=4187418181 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1932-6203&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1932-6203&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1932-6203&client=summon |